(VIANEWS) – Corcept Therapeutics Incorporated (CORT), Novo Nordisk A/S (NVO), Booz Allen Hamilton Holding Corporation (BAH) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Corcept Therapeutics Incorporated (CORT)
37.4% sales growth and 21.05% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.94.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 26.06. Meaning, the purchaser of the share is investing $26.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.05%.
2. Novo Nordisk A/S (NVO)
26.6% sales growth and 88.07% return on equity
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.71.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 47.75. Meaning, the purchaser of the share is investing $47.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 88.07%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Novo Nordisk A/S’s EBITDA is 2.55.
Sales Growth
Novo Nordisk A/S’s sales growth is 28% for the current quarter and 26.6% for the next.
Previous days news about Novo Nordisk A/S(NVO)
- According to Zacks on Tuesday, 26 March, "This field has so far been dominated by Novo Nordisk A/S (NVO Quick QuoteNVO – Free Report) and Eli Lilly and Co. (LLY Quick QuoteLLY – Free Report) ."
3. Booz Allen Hamilton Holding Corporation (BAH)
13.2% sales growth and 35.73% return on equity
Booz Allen Hamilton Holding Corporation provides management and technology consulting, analytics, engineering, digital, mission operations, and cyber solutions to governments, corporations, and not-for-profit organizations in the United States and internationally. The company offers consulting solutions for various domains, business strategies, human capital, and operations. It also provides analytics services, which focuses on delivering transformational solutions in the areas of artificial intelligence, such as machine learning, deep learning; data science, such as data engineering and predictive modeling; automation and decision analytics; and quantum computing. In addition, the company designs, develops, and implements solutions built on contemporary methodologies and modern architectures; delivers engineering services and solutions to define, develop, implement, sustain, and modernize complex physical systems; and provides cyber risk management solutions, such as prevention, detection, and cost effectiveness. Booz Allen Hamilton Holding Corporation was founded in 1914 and is headquartered in McLean, Virginia.
Earnings Per Share
As for profitability, Booz Allen Hamilton Holding Corporation has a trailing twelve months EPS of $3.11.
PE Ratio
Booz Allen Hamilton Holding Corporation has a trailing twelve months price to earnings ratio of 46.56. Meaning, the purchaser of the share is investing $46.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.73%.
Moving Average
Booz Allen Hamilton Holding Corporation’s worth is above its 50-day moving average of $140.24 and way above its 200-day moving average of $123.50.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Feb 9, 2024, the estimated forward annual dividend rate is 2.04 and the estimated forward annual dividend yield is 1.41%.
Volume
Today’s last reported volume for Booz Allen Hamilton Holding Corporation is 622213 which is 3.07% below its average volume of 641937.
Yearly Top and Bottom Value
Booz Allen Hamilton Holding Corporation’s stock is valued at $144.79 at 20:22 EST, below its 52-week high of $150.59 and way above its 52-week low of $88.59.
4. California Water Service Group (CWT)
11.4% sales growth and 3.73% return on equity
California Water Service Group, through its subsidiaries, provides water utility and other related services in California, Washington, New Mexico, and Hawaii. It is involved in the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, as well as for fire protection. The company offers its services to approximately 492,600 customer connections in 100 California communities; approximately 5,300 water and wastewater customer connections on the islands of Maui and Hawaii; approximately 36,600 customer connections in the Tacoma, Olympia, Graham, Spanaway, Puyallup, and Gig Harbor areas; and approximately 8,500 water and wastewater customer connections in the Belen, Los Lunas, Indian Hills, and Elephant Butte areas in New Mexico. It also engages in the provision of non-regulated water-related services, including operating of municipally owned water systems, privately owned water, and recycled water distribution systems; water system operation, meter reading, and billing services to private companies and municipalities; leasing of communication antenna sites on its properties to telecommunication companies; and billing of optional third-party insurance programs to its residential customers, as well as provides lab services. In addition, the company offers wastewater collection and treatment services. California Water Service Group was founded in 1926 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, California Water Service Group has a trailing twelve months EPS of $0.91.
PE Ratio
California Water Service Group has a trailing twelve months price to earnings ratio of 50.9. Meaning, the purchaser of the share is investing $50.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.73%.
Sales Growth
California Water Service Group’s sales growth is 40.2% for the present quarter and 11.4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.8%, now sitting on 794.63M for the twelve trailing months.
5. Merchants Bancorp (MBIN)
10% sales growth and 17.67% return on equity
Merchants Bancorp operates as the diversified bank holding company in the United States. It operates through Multi-family Mortgage Banking, Mortgage Warehousing, and Banking segments. The Multi-family Mortgage Banking segment engages in the mortgage banking, which originates and services government sponsored mortgages including bridge financing products to refinance, acquire, or reposition multi-family housing projects, and construction lending for multi-family and healthcare facilities; offers customized loan products for need-based skilled nursing facilities, independent living, assisted living, and memory care; and tax credit equity syndicator. Its Mortgage Warehousing segment funds agency eligible residential loans including origination, purchase, and sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment offers a range of financial products and services to consumers and businesses, which includes retail banking, commercial lending, agricultural lending, retail and correspondent residential mortgage banking, and small business administration lending. Merchants Bancorp was founded in 1990 and is headquartered in Carmel, Indiana.
Earnings Per Share
As for profitability, Merchants Bancorp has a trailing twelve months EPS of $5.64.
PE Ratio
Merchants Bancorp has a trailing twelve months price to earnings ratio of 7.6. Meaning, the purchaser of the share is investing $7.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.67%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 27.1% and 7.6%, respectively.
Moving Average
Merchants Bancorp’s worth is higher than its 50-day moving average of $41.93 and way higher than its 200-day moving average of $32.91.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 0.36 and the estimated forward annual dividend yield is 0.84%.
6. Halozyme Therapeutics (HALO)
8.8% sales growth and 222.07% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.1.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 19.09. Meaning, the purchaser of the share is investing $19.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 222.07%.
7. CBIZ (CBZ)
8.1% sales growth and 16.08% return on equity
CBIZ, Inc. provides financial, insurance, and advisory services in the United States and Canada. The company operates through three segments: Financial Services, Benefits and Insurance Services, and National Practices. The Financial Services segment offers accounting and tax, government healthcare consulting, financial advisory, valuation, and risk and advisory services. The Benefits and Insurance Services provides group health benefits consulting, payroll, property and casualty, and retirement plan services. The National Practices segment offers managed networking and hardware, and health care consulting services. It primarily serves small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises. The company was founded in 1987 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, CBIZ has a trailing twelve months EPS of $2.39.
PE Ratio
CBIZ has a trailing twelve months price to earnings ratio of 31.46. Meaning, the purchaser of the share is investing $31.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.08%.
Volume
Today’s last reported volume for CBIZ is 872283 which is 184.55% above its average volume of 306539.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CBIZ’s EBITDA is 2.7.
8. Global Payments (GPN)
5.5% sales growth and 4.44% return on equity
Global Payments Inc. provides payment technology and software solutions for card, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through two segments, Merchant Solutions and Issuer Solutions. The Merchant Solutions segment offers authorization, settlement and funding, customer support, chargeback resolution, terminal rental, sales and deployment, payment security, and consolidated billing and reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added solutions and services, such as point-of-sale software, analytics and customer engagement, payroll and reporting, and human capital management. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments, account payables, and electronic payment alternatives solutions for businesses and governments. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Global Payments has a trailing twelve months EPS of $3.77.
PE Ratio
Global Payments has a trailing twelve months price to earnings ratio of 35.59. Meaning, the purchaser of the share is investing $35.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.44%.
